What the drug is doing to your stomach
GLP-1 receptor agonism slows gastric emptying. Food stays in the stomach longer than you are used to, which is a substantial part of why you feel full sooner and stay full longer. It is also where most of the nausea comes from. The mechanism you want and the side effect you do not are the same mechanism.
Why the timing is what it is
The weekly injectables have long half-lives. Semaglutide's is around a week. That means the concentration in your blood after a dose increase does not jump on injection day and then fall away. It climbs over several days and keeps climbing toward a new steady state across several weeks.
So the hardest day is usually not the day you inject. It is commonly two to four days later, and the first week after a step up is reliably worse than the third or fourth week at that same dose. People who expect the reaction on injection day often conclude the drug is not affecting them, then get caught out mid-week.
Why it fades
The slowed gastric emptying attenuates with continued exposure more than the appetite effect does. Your stomach adapts to the drug faster than your appetite does, which is exactly the adaptation you want and is the entire logic of titration.
This is why a dose that made you miserable in week one is often unremarkable by week six, and why moving up faster than four-week intervals is the most common avoidable cause of a bad first month.
What tends to help
- Smaller volumes at a time. The immediate problem is mechanical: volume sitting in a stomach that is emptying slowly.
- Less fat in the meal. Fat slows gastric emptying further, on top of what the drug is already doing.
- Stopping at the first real signal of fullness rather than at the end of the portion. The signal arrives earlier than you are used to and is easy to eat straight past.
- Fluids between meals rather than with them, so you are not adding volume to a full stomach.
- Staying ahead of dehydration. Vomiting plus poor fluid intake is the route to acute kidney injury, and it is the mechanism behind a meaningful share of the serious adverse events in this class.
When it is not just nausea
- Severe, persistent abdominal pain, particularly radiating through to the back, needs assessment for pancreatitis. This is the one to act on rather than wait out.
- Pain under the right ribs after fatty meals can be gallbladder, which occurs more often on these drugs than on placebo.
- Vomiting that stops you keeping fluids down is a call to your prescriber, not something to manage alone.
- Anything that makes you consider skipping doses is worth raising, because holding a dose deliberately is a normal clinical decision and skipping unpredictably is not.
Holding is not failing
The titration schedule is a ceiling, not a timetable. There is no requirement to reach the maximum dose, and a substantial number of people get the result they want at an intermediate dose and stay there. If the only way up is through weeks of feeling ill, that is information, not a test of resolve.
Sources
- Wegovy and Ozempic prescribing information, Novo Nordisk
- Mounjaro and Zepbound prescribing information, Eli Lilly
- Published pharmacokinetic data for once-weekly GLP-1 receptor agonists